@article {Mendy2020.08.11.20172676, author = {Angelico Mendy and Jason L. Keller and Senu Apewokin and Ardythe L. Morrow}, title = {Is Blood Type Associated with COVID-19 Severity?}, elocation-id = {2020.08.11.20172676}, year = {2020}, doi = {10.1101/2020.08.11.20172676}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Blood type purportedly influences susceptibility to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, but whether it affects severity of coronavirus disease 2019 (COVID-19) is unclear. Therefore, we examined the association of blood type and rhesus with hospitalization and disease severity among 428 COVID-19 patients diagnosed at the University of Cincinnati health system. In the sample, 50.2\% of participants had the blood type O, 38.7\% had the blood type A, 17.5\% had the blood type B, and 3.5\% had the blood type AB. In analysis adjusted for sociodemographic characteristics and comorbidities, the blood types A (OR: 0.90, 95\% CI: 0.54, 1.50), B (OR: 0.93, 95\% CI: 0.51, 1.69), AB (OR: 0.69, 95\% CI: 0.20, 2.41), and O (OR: 1.18, 95\%: 0.74, 1.98) were not associated with hospitalization for COVID-19. Similarly, the blood types A (OR: 0.93, 95\% CI: 0.52, 1.65), B (OR: 0.92, 95\% CI: 0.46, 1.84), AB (OR: 0.30, 95\% CI: 0.04, 2.44), and O (OR: 1.25, 95\%: 0.73, 2.14) were not associated with admission to intensive care unit or death in COVID-19. In conclusion, blood type is not associated with hospitalization or disease severity in COVID-19; therefore, it may not be useful marker for identifying patients at risk for severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot ApplicableFunding StatementAngelico Mendy contribution was partly funded by grant P30 ES006096 from the US NIH. The project described was supported by the National Center for Advancing Translational Sciences of the NIH, under Award Number 5UL1TR001425-03.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Cincinnati Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SAS codes and datasets are available for reproducing the results upon reasonable request}, URL = {https://www.medrxiv.org/content/early/2020/08/14/2020.08.11.20172676}, eprint = {https://www.medrxiv.org/content/early/2020/08/14/2020.08.11.20172676.full.pdf}, journal = {medRxiv} }